Molecular-weight-dependent pharmacokinetics and cytotoxic properties of cisplatin complexes prepared with chondroitin sulfate A and C

International Journal of Pharmaceutics

Volumn 240, Issue 1-2, 2002, Pages 23-31

  Zhang, Jing Shi ^a   Imai, Teruko ^a   Suenaga, Ayaka ^a   Otagiri, Masaki ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Chondroitin sulfate A; Chondroitin sulfate C; Cisplatin; Complex; Macromolecular carrier; Pharmacokinetics

Indexed keywords

CISPLATIN CHONDROITIN SULFATE A1; CISPLATIN CHONDROITIN SULFATE A2; CISPLATIN CHONDROITIN SULFATE C1; CISPLATIN CHONDROITIN SULFATE C2; CISPLATIN DERIVATIVE; PLATINUM; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG URINE LEVEL; HUMAN; HUMAN CELL; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CHONDROITIN SULFATES; CISPLATIN; COLONIC NEOPLASMS; DRUG CARRIERS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, INBRED STRAINS; MOLECULAR WEIGHT; NEOPLASM TRANSPLANTATION; RATS; RATS, WISTAR; SARCOMA 180; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0037142257     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(02)00111-4     Document Type: Article

References (22)

1. Chondroitin-4-sulfate protects high-density lipoprotein against copper-dependent oxidation
2. Newer insights into cisplatin nephrotoxicity
3. Cumulative toxicities from cisplatin therapy and current cytoprotective measures
4. The role of polymer conjugates in the diagnosis and treatment of cancer
5. Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum (II) (DDP) in the tumored rat
6. HPMA copolymer platinates as novel antitumour agents: In vitro properties, pharmacokinetics and antitumour activity in vitro
7. Urinary excretion of sulfated polysaccharides administered to Wistar rats suggests a renal permselectivity to these polymers based on molecular size
8. Modulation of platinum-induced toxicities and therapeutic index: Mechanistic insights and first- and second-generation protecting agents
9. Alteration of pharmacokinetics and nephrotoxicity of cisplatin by alginates
10. The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease
11. Clinical development of platinum complexes in cancer therapy: An history perspective and an update
12. Tumoritropic and lymphotropic principles of macromolecular drugs
13. Metabolic fate of exogenous chondroitin sulfate in the experimental animal
14. Fundamental studies with cisplatin
15. Cis-platinum (II) complexes of carboxymethyl-dextran as potential antitumor agents. II. In vitro and in vivo activity
16. Soluble polymers as carriers of cis-platinum
17. Cisplatin and its analogues in the treatment of advamced breast cancer: A review
18. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats
19. Combination studies with gemcitabine in the treatment of non-small-cell lung cancer
20. Macromolecular carrier systems for targeted drug delivery: Pharmacokinetic considerations on biodistribution
21. Effect of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin
22. Stability of a cisplatin-chondroitin sulfate A complex in plasma and kidney in terms of protein binding